Výsledky vyhledávání - "Dragan Kiselicki"

Akademický článek

Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer

Autor: Elke Jäger, Julia Karbach, Claudia Wahle, Dragan Kiselicki, Kathrin Brand, Evgueni Sinelnikov, Dirk Gustavus, Hans Hoffmeister, Hans-Bernd Prisack, Akin Atmaca

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 1 (2023)

Adoptive transfer of autologous tumor-specific lymphocytes represents a viable treatment method for patients with advanced malignancies. Here, we report a patient’s case with metastatic hormone-refractory New York esophageal squamous cell carcinoma

Externí odkaz: https://doaj.org/article/59a10633aff74d6bb16b5bc67cc12c34

Zobrazit plný text záznamu

Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer

Autor: Julia Karbach, Dragan Kiselicki, Kathrin Brand, Claudia Wahle, Evgueni Sinelnikov, Dirk Gustavus, Hans Hoffmeister, Hans-Bernd Prisack, Akin Atmaca, Elke Jäger

Publikováno v: Journal for ImmunoTherapy of Cancer. 11:e005847

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::92f77e03bd969bd1db5e34b0b83bb996
https://doi.org/10.1136/jitc-2022-005847

Zobrazit plný text záznamu

Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors

Autor: Daniel Wilhelm Mueller, Elke Jäger, Mohammad-Reza Rafiyan, Dragan Kiselicki, Regina Eickhoff, Timursah Habibzade, Marina Schaaf, Thorsten Oliver Goetze, Salah-Eddin Al-Batran

Publikováno v: Journal of Clinical Oncology. 39:2518-2518

2518 Background: Stratum D of the INSIGHT platform trial evaluates s.c. eftilagimod alpha (efti, IMP321) combined with avelumab in advanced solid tumors. Efti is an MHC class II agonist which activates antigen-presenting cells followed by CD8 T-cell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5513cc3d65ac33b5427ef13185897a78
https://doi.org/10.1200/jco.2021.39.15_suppl.2518

Zobrazit plný text záznamu

Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (LAG-3Ig fusion protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: Results from stratum D of the INSIGHT platform trial

Autor: Salah-Eddin Al-Batran, Daniel Wilhelm Mueller, Thorsten Oliver Goetze, Mohammad-Reza Rafiyan, Dragan Kiselicki, Regina Eickhoff, Elke Jaeger

Publikováno v: Journal of Clinical Oncology. 38:3099-3099

3099 Background: Stratum D of the INSIGHT study investigates the feasibility and safety of s.c. application of IMP321 (eftilagimod alpha) combined with the PD-L1 inhibitor avelumab in advanced stage solid tumors. The MHC class II agonist IMP321 activ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::db90d3181597d390c11387a676cd077b
https://doi.org/10.1200/jco.2020.38.15_suppl.3099

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání